118 related articles for article (PubMed ID: 16272749)
1. Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.
Jin M; Shimada T; Shintani M; Yokogawa K; Nomura M; Miyamoto K
Drug Metab Pharmacokinet; 2005 Oct; 20(5):324-30. PubMed ID: 16272749
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B.
Ishizaki J; Ito S; Jin M; Shimada T; Ishigaki T; Harasawa Y; Yokogawa K; Takami A; Nakao S; Miyamoto K
Biopharm Drug Dispos; 2008 May; 29(4):195-203. PubMed ID: 18240156
[TBL] [Abstract][Full Text] [Related]
3. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.
Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K
Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676
[TBL] [Abstract][Full Text] [Related]
4. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.
Yokogawa K; Shimada T; Higashi Y; Itoh Y; Masue T; Ishizaki J; Asahi M; Miyamoto K
Biochem Pharmacol; 2002 Feb; 63(4):777-83. PubMed ID: 11992648
[TBL] [Abstract][Full Text] [Related]
5. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.
Jin M; Shimada T; Yokogawa K; Nomura M; Ishizaki J; Piao Y; Kato Y; Tsuji A; Miyamoto K
Biochem Pharmacol; 2006 Oct; 72(8):1042-50. PubMed ID: 16939683
[TBL] [Abstract][Full Text] [Related]
6. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.
Fricker G; Drewe J; Huwyler J; Gutmann H; Beglinger C
Br J Pharmacol; 1996 Aug; 118(7):1841-7. PubMed ID: 8842452
[TBL] [Abstract][Full Text] [Related]
7. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
Ikemura K; Inoue K; Mizutani H; Oka H; Iwamoto T; Okuda M
Eur J Pharmacol; 2012 Sep; 690(1-3):192-201. PubMed ID: 22749977
[TBL] [Abstract][Full Text] [Related]
8. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
9. Influence of cytarabine and cyclophosphamide on the disposition kinetics of cyclosporin A after bone marrow transplantation.
Shimada T; Aoki Y; Yokogawa K; Nomura M; Ishizaki J; Nishigami J; Miyamoto K
Transpl Int; 2003 Nov; 16(11):788-93. PubMed ID: 12844214
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition.
Zhai XJ; Shi F; Chen F; Lu YN
Food Chem Toxicol; 2013 Dec; 62():323-8. PubMed ID: 24013073
[TBL] [Abstract][Full Text] [Related]
11. Effect of clarithromycin on the bioavailability of cyclosporin in rats.
Ohba M; Ohnishi N; Komada F; Iwakawa S; Okumura K
Biol Pharm Bull; 1996 May; 19(5):733-7. PubMed ID: 8741585
[TBL] [Abstract][Full Text] [Related]
12. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.
Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
J Pharm Pharmacol; 2004 Oct; 56(10):1259-66. PubMed ID: 15482640
[TBL] [Abstract][Full Text] [Related]
13. Effect of atropine on gastrointestinal motility and the bioavailability of cyclosporine A in rats.
Quijano RF; Ohnishi N; Umeda K; Komada F; Iwakawa S; Okumura K
Drug Metab Dispos; 1993; 21(1):141-3. PubMed ID: 8095208
[TBL] [Abstract][Full Text] [Related]
14. Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats.
Mizuno N; Takagi C; Yamamoto N; Takahashi K
Biol Neonate; 1998; 74(3):243-52. PubMed ID: 9691165
[TBL] [Abstract][Full Text] [Related]
15. Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression.
Goralski KB; Acott PD; Fraser AD; Worth D; Sinal CJ
Drug Metab Dispos; 2006 Feb; 34(2):288-95. PubMed ID: 16303871
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine.
Takara K; Ohnishi N; Horibe S; Yokoyama T
Drug Metab Dispos; 2003 Oct; 31(10):1235-9. PubMed ID: 12975332
[TBL] [Abstract][Full Text] [Related]
17. Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.
Liu Y; Luo X; Yang C; Yang T; Zhou J; Shi S
Mol Med Rep; 2016 Oct; 14(4):3073-85. PubMed ID: 27510982
[TBL] [Abstract][Full Text] [Related]
18. In situ intestinal absorption of cyclosporine A solid dispersion in rats.
Liu C; Zhu S; Zhou Y; Wei Y; Pei Y
Drug Dev Ind Pharm; 2008 Jun; 34(6):627-31. PubMed ID: 18568913
[TBL] [Abstract][Full Text] [Related]
19. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.
Terao T; Hisanaga E; Sai Y; Tamai I; Tsuji A
J Pharm Pharmacol; 1996 Oct; 48(10):1083-9. PubMed ID: 8953513
[TBL] [Abstract][Full Text] [Related]
20. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
